Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK2 | Q92630 | 8/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | BTK | Q06187 | 2/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2328664 | 0.85 | CCNC (0.48) | DYRK2EGFRBTK | |
| Tert-Butyl Formate SCHEMBL27789630 | 0.85 | CCNC (0.44) | EGFRBTK | |
| SCHEMBL12789207 | 0.80 | CCNC (0.49) | — | |
| SCHEMBL2327670 | 0.79 | CSNK2A1 (0.45) | EGFRBTKHDAC4MAPTMEN1 | |
| SCHEMBL22431589 | 0.74 | EGFR (0.77) | EGFRBTK | |
| SCHEMBL2324607 | 0.73 | DYRK2 (0.56) | DYRK2GPR119MAPTMEN1KMT2A | |
| SCHEMBL13872072 | 0.72 | MEN1 (0.57) | GPR119HDAC4CRBNMEN1KMT2A | |
| SCHEMBL3643667 | 0.72 | ABL1 (0.41) | EGFRBTKCDK2 | |
| SCHEMBL13605626 | 0.70 | PDPK1 (0.52) | BTKGPR119MAPTMEN1KMT2A | |
| SCHEMBL24756629 | 0.70 | EPHX2 (0.48) | GPR119MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288540-B2 | 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors | IRM LLC (BM) | 2012-10-16 | — | — | US | disclosed |
| EP-2190836-B1 | 2-HETEROARYLAMINO-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-08-17 | — | — | EP | disclosed |
| US-20110053952-A1 | 2-HETEROARYLAMINO-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053952-A1 | 2-HETEROARYLAMINO-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | FYN, LCK, ERBB2 | DYRK2 85/4885EGFR 115/4885BTK 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.